The Science of Obesity



Obesity is not just a lifestyle issue; it is a chronic disease¹⁻³

Obesity is recognized as a chronic disease and a significant threat to public health by national organizations such as AACE, ACE, and AMA.¹⁻³

"Our AMA recognizes obesity as a disease state with multiple pathophysiological aspects requiring a range of interventions to advance obesity treatment and prevention."¹

American Medical Association (AMA)

"Obesity is a complex, multifactorial condition characterized by excess body fat. It must be viewed as a chronic condition that essentially requires perpetual care, support, and follow-up. Obesity causes many other diseases, and it warrants recognition by health-care providers and payers."²

American Association of Clinical Endocrinology/ American College of Endocrinology Obesity Task Force

Obesity is often classified by a body mass index (BMI) of 30 kg/m² or higher.³

AACE=American Association of Clinical Endocrinology; ACE=American College of Endocrinology; AMA=American Medical Association.

Obesity Is a Highly Prevalent Chronic Disease Within the United States

Nearly 3 in 4 US Adults Have Obesity or Overweight⁴⁻⁶

The Center for National Health Statistics found that in adults aged \geq 20 years between 2017 and 2018⁴⁻⁶:



Nearly **1 in 3** suffered from overweight (BMI 25 kg/m²-29.9 kg/m²)




Nearly **2 in 5** suffered from obesity (BMI ≥30 kg/m²)



Nearly **1 in 10** suffered from severe obesity (BMI ≥40 kg/m²)

Obesity Is Associated With Other Health Conditions^{7,8}



Why Do People Eat? For Hunger or for Pleasure?

(())

Food intake is affected by hormones from the body that signal to the brain.⁹ Eating for hunger is driven by hunger and satiety pathways in the brain.⁹⁻¹³

• Appetite hormones released from the intestine, adipose tissue, pancreas, and stomach target the brain




Eating for pleasure is driven by food reward pathways in the brain.

The Tug-of-War of Weight Management^{14,15}

After weight loss, the body tries to put weight back on.^{14,15}

- Even if people with obesity achieve weight loss through calorie reduction, this weight loss can be difficult to maintain because of the body's metabolic and hormonal responses
- In people with obesity, the body will try to put the weight back on for at least 12 months after weight loss



Weight loss due to calorie restriction may cause the body to react by slowing metabolism and altering appetite-regulating hormones in a process called metabolic adaptation, making long-term weight management difficult^{14,15}

Clinical Guidelines for Treatment of Obesity

Evidence-based guidelines from AHA/ACC/TOS suggest a stepwise approach to obesity management, which may include pharmacotherapy or bariatric surgery.^{3,a}

Treatment	BMI Category (kg/m²)				
	25-26.9	27-29.9	30-34.9	35-39.9	≥40
Diet, physical activity, and behavior therapy	Yes, with comorbidities	Yes	Yes	Yes	Yes
Pharmacotherapy		Yes, with comorbidities	Yes	Yes	Yes
Surgery				Yes, with comorbidities	Yes

AHA/ACC/TOS Evidence-Based Guidelines for Adults³

ACC=American College of Cardiology; AHA=American Heart Association; TOS=The Obesity Society.

^aYes alone means that the treatment is indicated regardless of presence or absence of comorbidities. The solid arrow signifies the point at which treatment may be initiated.

Weight Loss of 2% to >15% May Lead to Clinical Improvements in Many Obesity-Related Complications¹⁶

2.5%	helps prevent progression to diabetes; maximal impact at 10%	Glycemic improvement—diabetes prevention in impaired glucose tolerance
2% to 5%	improves ovulatory cycles; greater weight loss associated with greater improvement	Polycystic ovarian syndrome and infertility
2.5% to >15%	greater weight loss associated with greater improvement; true for all BMI classes	 Glycemic improvement—Type 2 diabetes^a Triglyceride reduction
5% to 10%	improves knee functionality, speed, walk distance, and pain	Knee pain and function in osteoarthritis
5% to >15%	greater weight loss associated with greater improvement	 HDL cholesterol increase^b Hepatic steatosis reduction

HDL=high-density lipoprotein.

^aImprovement in fasting glucose and hemoglobin A1c is observed beginning at a weight loss of ≥2 to <5%. ^bGreater weight loss is not associated with greater improvement for BMI >40 kg/m².

References: 1. Recognition of Obesity as a Disease H-440.842. American Medical Association website. Accessed August 10, 2022. https://policysearch.ama-assn.org/policyfinder/detail/obesity?uri=%2FAMADoc%2FHOD.xml-0-3858.xml 2. Mechanick JI, Garber AJ, Handelsman Y, Garvey WT. American Association of Clinical Endocrinologists' position statement on obesity and obesity medicine. Endocr Pract. 2012;18(5):642-648. 3. Jensen MD, Ryan DH, Apovian CM, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; The Obesity Society. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;24(25 suppl 2):S102-S138. 4. Centers for Disease Control and Prevention. National Center for Health Statistics. Health, United States, 2019 [supplement]. Accessed August 10, 2022. https://www.cdc.gov/nchs/data/hus/2019/026-508.pdf 5. Department of Health and Human Services. National Center for Health Statistics. Data brief No 360. Accessed July 27, 2022. https://www.cdc.gov/nchs/data/databriefs/db360-h.pdf 6. Defining adult overweight & obesity. Centers for Disease Control and Prevention website. Accessed August 10, 2022. https://www.cdc.gov/obesity/basics/adult-defining.html 7. Garvey WT, Mechanick JI, Brett EM, et al; Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(suppl 3):1-203. 8. Cancers associated with overweight and obesity makeup 40 percent of cancers diagnosed in the United States. Centers for Disease Control website. Published October 3, 2017. Accessed August 10, 2022. https://www.cdc.gov/media/ releases/2017/p1003-vs-cancer-obesity.html 9. Farr OM, Li CR, Mantzoros CS. Central nervous system regulation of eating: insights from human brain imaging. Metab Clin Exp. 2016;65:699-713. 10. Druce MR, Small CJ, Bloom SR. Minireview: gut peptides regulating satiety. Endocrinology. 2004;145:2660-2665. 11. Berthoud HR, Münzberg H, Morrison CD. Blaming the brain for obesity: integration of hedonic and homeostatic mechanisms. Gastroenterology. 2017;152(7):1728-1738. 12. Guyenet SJ, Schwartz MW. Regulation of food intake, energy balance, and body fat mass: implications for the pathogenesis and treatment of obesity. J Clin Endocr Metab. 2012;97(3):745-755. 13. Cassidy RM, Ton Q. Hunger and satiety gauge reward sensitivity. Front Endocrinol. 2017;8:104. 14. Lam YY, Ravussin E. Analysis of energy metabolism in humans: a review of methodologies. Mol Metab. 2016;5(11):1057-1071. 15. Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597-1604. 16. Ryan DH, Yockey SR. Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over. Curr Obes Rep. 2017:6:187-194.



Novo Nordisk is a registered trademark of Novo Nordisk A/S.